BioCardia raises $4.4 million in equity financing

BioCardia Inc. (NASDAQ: BCDA) completed a $4.4 million equity financing through the sale of 3,509,604 shares at an average price of $1.279 per share on June 5, 2026, according to a company statement.

The Sunnyvale, California-based company said no warrants were issued in this capital raise. BioCardia stated the net proceeds are expected to extend its cash runway into the first quarter of 2027, beyond its anticipated Japan PMDA submission.

The company indicated that if currently outstanding warrants from previous financings are exercised in full for cash, the cash runway would extend beyond PMDA approval and into first commercial sales.

BioCardia develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's pipeline includes CardiAMP autologous and CardiALLO allogeneic cell therapies, supported by its Helix biotherapeutic delivery and Morph vascular navigation platforms.

The company outlined upcoming milestones for 2026, including publication of a CardiAMP HF manuscript and submission of CardiAMP HF to Japan's PMDA in the fourth quarter of 2026.

You May Also Be Interested In

• CalPrivate Bank names Andra Frazier as chief credit officer
• Textron Aviation delivers 500th Cessna Citation CJ4 to Philippines customer
• PicPay integrates ChatGPT to let users query account data